Abstract：Objective：To observe the clinical effect of modified Ruyongxiao Prescription combined with mammotome minimally invasive surgery on plasma cell mastitis (PCM). Methods： A total of 80 cases of PCM patients were selected as the study objects and divided into the control group and the observation group according to the random number table method， with 40 cases in each group. Both groups were treated with mammotome minimally invasive surgery. After surgery， the control group was given intravenous infusion of Ceftazidime and the observation group was given the oral administration of Ruyongxiao Prescription based on the treatment of the control group. Traditional Chinese medicine (TCM) syndrome scores ， Visual Analogue Scale (VAS) scores ， and the levels of hypersensitivity C-reactive protein (hs- CRP)，interleukin- 6 (IL- 6)，and tumor necrosis factor- α (TNF- α) in serum were compared between the two groups； the incidence of postoperative adverse reactions was observed and compared between the two groups. Results：After 2 weeks and 4 weeks of treatment，TCM syndrome scores and VAS scores in the two groups were decreased when compared with those before treatment (P＜0.05)，and the above scores in the observation group were lower than those in the control group at the same time point (P＜0.05). After treatment， the levels of IL- 6， TNF- α and hs- CRP in the two groups were decreased when compared with those before treatment (P＜0.05)，and the levels of IL-6，TNF-α and hs-CRP in the observation group were lower than those in the control group (P＜0.05). After surgery， the incidence of adverse reactions was 2.5% in the observation group，lower than that of 17.5% in the control group (P＜ 0.05). Conclusion： Modified Ruyongxiao Prescription combined with mammotome minimally invasive surgery has a significant curative effect in the treatment of PCM， which can effectively reduce clinical symptoms，relieve pain and discomfort and reduce the levels of inflammatory factors，with high safety.